Baker SD et al. DYPD testing: Time to put patient safety first. J Clin Oncol 2023;[Online ahead of print]. Abstract
Burnett H et al. Impact of regorafenib dose optimization on comparative outcomes in the treatment of relapsed/refractory metastatic colorectal cancer (mCRC). ESMO 2022;Abstract 400P.
Cercek A et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363-76. Abstract
Chalabi M et al. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. ESMO 2022;Abstract LBA7.
Cohen SA et al. Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer. ESMO 2022;Abstract 319MO.
Cremolini C et al. Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO. ASCO 2022;Abstract LBA3505.
Dasari NA et al. FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. ESMO 2022;Abstract LBA25.
Diaz LA Jr et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022;23(5):659-70. Abstract
El-Khoueiry A. Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. ESMO GI 2022;Discussant Abstract.
Kaltenmeier C et al. Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States. HPB (Oxford) 2022;24(10):1688-96. Abstract
Kasi PM. ctDNA Assays: Exploring their clinical use in oncology care. ASCO Daily News, January 13, 2022. https://dailynews.ascopubs.org/do/ctdna-assays-exploring-their-clinical-use-oncology-care.
Kopetz S et al. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: Patient-reported outcomes from BEACON CRC. ESMO Open 2022;7(3):100477. Abstract
Kotani D et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29(1):127-34. Abstract
Kuboki Y et al. Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. ESMO 2022;Abstract 3150.
Lentz RW, et al. Innate immune checkpoint inhibitors: The next breakthrough in medical oncology? Mole Cancer Ther 2021;20(6):961-74. Abstract
Lentz RW et al. Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite stable metastatic colorectal cancer (AGICC-ALX148 21CRC01, NCT05167409). Gastrointestinal Cancers Symposium 2023;Abstract TPS257.
Ludford K et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol 2023;41(20):2181-90. Abstract
Malla M et al. Using circulating tumor DNA in colorectal cancer: Current and evolving practices. J Clin Oncol 2022;40(24):2846-57. Abstract
Martinelli E et al. Evidence of therapeutic effectiveness of III line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials. Gastrointestinal Cancers Symposium 2022;Abstract O-7.
Morris VK et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 2023;41(3):678-700. Abstract
Overman MJ et al. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. ASCO 2022;Abstract 3510.
Strickler JH et al. Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. ESMO 2022;Abstract LBA27.
Strickler JH et al. MOUNTAINEER: Open-label, phase 2 study of tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017). Gastrointestinal Cancers Symposium 2022;Abstract LBA-2.
Tabernero J et al. Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study. Gastrointestinal Cancers Symposium 2023;Abstract 4.
Tabernero J et al. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC). ESMO 2022;Abstract LBA26.
Taieb J et al. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results from the phase IIIb single-arm PRECONNECT study by duration of therapy. BMC Cancer 2023;23(1):94. Abstract
Tie J et al. Circulating tumor DNA analysis guiding adjuvant therapy in Stage II colon cancer. N Engl J Med 2022;386(24):2261-72. Abstract
Yaeger R et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med 2023;388(1):44-54. Abstract
Yoshino T et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. ASCO 2022;Abstract LBA1.